Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,296.5 pence per share; lowest price paid was 1,272.0 pence per share.
- Treasury Holdings (Settled): 502,996,816 shares (9.01% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,996,816 shares (9.93% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,078,010,910 shares.
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the percentage of shares held in Treasury increased to 9.93% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,078,010,910) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the settlement status of the 1,000,000 shares purchased on August 30, 2011.
- Review the total Treasury share count (503,996,816) to assess the impact on total voting rights (9.93%).